/
FENC
$11.03+$0.01 (+0.09%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$382.8M
35M shares
52-week range
$5.65 – $11.31
95% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$3.74
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $170.0K | $0 | $1.5M | $21.3M | $47.5M | $44.6M |
| Cost of revenue | $0 | $0 | $0 | $0 | $86.0K | $1.3M | $3.2M | $3.8M |
| Gross profit | $0 | $0 | $170.0K | $0 | $1.4M | $20.0M | $44.4M | $40.9M |
| Gross margin | — | — | 100.0% | — | 94.4% | 94.1% | 93.3% | 91.6% |
| R&D | $5.0M | $5.7M | $5.1M | $5.0M | $3.5M | $56.0K | $307.0K | $250.0K |
| Operating income | −$10.4M | −$13.3M | −$17.9M | −$17.2M | −$22.7M | −$13.1M | $2.5M | −$6.3M |
| EBITDA | $521.0K | −$13.1M | −$18.1M | −$17.2M | −$22.6M | −$12.4M | $4.8M | −$7.5M |
| Net income | −$9.9M | −$13.1M | −$18.1M | −$17.3M | −$23.7M | −$16.0M | −$436.0K | −$9.7M |
| Net margin | — | — | -10652.4% | — | -1544.9% | -75.5% | -0.9% | -21.8% |
| EPS (diluted) | -0.52 | -0.63 | -0.76 | -0.67 | -0.95 | -0.60 | -0.02 | -0.36 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $70M | $0.25 | $0.17–$0.33 | 4 |
| 2027 | $100M | $0.90 | $0.62–$1.22 | 4 |
| 2028 | $135M | $1.52 | $1.02–$2.01 | 3 |
| 2029 | $189M | $2.48 | $2.28–$2.66 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Fennec Pharmaceuticals Inc. Common Stock
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
www.fennecpharma.com- Employees
- 35
- IPO / List date
- Jan 28, 2002
- HQ
- RESEARCH TRIANGLE PARK, NC
Held by traders on TradeandTell
No one on the platform currently holds FENC.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 20,000 | $154.0K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded FENC yet.
